Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 4/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18791644 | 0.82 | MEN1 (0.39) | IRAK4 | |
| SCHEMBL20571411 | 0.79 | KDM4E (0.37) | TNFIDH1IRAK4KDM1ANLRP3 | |
| SCHEMBL20571764 | 0.76 | KMT2A (0.46) | — | |
| SCHEMBL13375796 | 0.72 | IRAK4 (0.46) | IRAK4 | |
| SCHEMBL27405070 | 0.71 | TRPA1 (0.43) | IDH1EGLN1TRPA1 | |
| SCHEMBL10264748 | 0.68 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL10268452 | 0.67 | CHRM4 (0.54) | — | |
| SCHEMBL27303358 | 0.67 | CCR6 (0.48) | — | |
| SCHEMBL12144769 | 0.66 | KIF11 (0.36) | — | |
| SCHEMBL12655634 | 0.62 | KIF11 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | TNF 3515/4885IDH1 286/4885IRAK4 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.